State Street Corp's Strategic Acquisition in Vir Biotechnology Inc
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
We're Keeping An Eye On Vir Biotechnology's (NASDAQ:VIR) Cash Burn Rate
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta And Hepatitis B Programs At AASLD's The Liver Meeting 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company